Boston Scientific Cognis and Teligen
This article was originally published in The Gray Sheet
Executive Summary
Firm announces FDA approval May 13 for its next-generation high-voltage cardiac rhythm management platform devices - the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and Teligen implantable caridoverter defibrillator (ICD). The devices "are among the world's smallest and thinnest high-energy devices" at 32.5 cc and 31.5 cc in volume, respectively, and under 10 mm thick, the firm states. Key Cognis features include SmartDelay to quickly propose programmable device settings and Electronic Repositioning with six different options for stimulating the left side of the heart. Teligen features include Quick Convert for pacing treatment of ventricular tachycardias and Enhanced AV Search to minimize unnecessary right ventricular pacing. Both devices also provide extended battery longevity over previous Boston Scientific offerings